Similar classifiers could be relevant for many other categories of biomarkers which are needed for diagnostic, prognostic, or therapeutic purposes, such as prognostic scores [Gleason score for prostate tumors (14, 26)], viral tumor status [Human Papilloma Virus for cervical or oropharynx cancers (2, 24)], protein expression [targeted inhibitors for ALK-positive lung cancers (27) or immune checkpoint inhibitors in tumors expressing PDL1], gene mutations (targeted inhibitors for BRAF V600-mutated melanoma). This evidence concerns the gene ALK and oropharynx cancer.